Biotech, pharma, and nonprofit organization leaders ponder how to move abandoned compounds to patients
In the race to get drugs to patients, not every promising candidate that clears the initial hurdle of Phase 1 safety trials makes it to market. Some wipe out because of safety concerns that emerge later. Some don’t pass the high bar of efficacy. Even those that clear those obstacles sometimes get abandoned, not for scientific reasons but because of business decisions.